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Abstract 
Many drugs can induce liver injury, characterized by hepatocellular, cholestatic or 
mixed hepatocellular-cholestatic lesions. While an inflammatory stress is known to 
aggravate hepatocellular injury caused by some drugs much less evidence exists for 
cholestatic features. In this study, the influence of pro-inflammatory cytokines (IL-6, 
IL-1β and TNF-α), either individually or combined, on cytotoxic and cholestatic 
properties of antibiotics was evaluated using differentiated HepaRG cells. Six 
antibiotics of various chemical structures and known to cause cholestasis and/or 
hepatocellular injury in clinic were investigated. Caspase-3 activity was increased 
with all these tested hepatotoxic drugs and except with erythromycin, was further 
augmented in presence of cytokines mainly when these were co-added as a mixture. 
TNF-α and IL-1β aggravated cytotoxicity of TVX more than IL-6. Bile canaliculi (BC) 
dilatation induced by cholestatic drugs was increased by co-treatment with IL-6 and 
IL-1β but not with TNF-α. Reduced accumulation of carboxy-dichlorofluorescein, a 
substrate of the multi-drug resistance-associated protein 2, in antibiotic–induced 
dilatated BC, was further extended in presence of individual or mixed cytokines. In 
conclusion, our data demonstrate that pro-inflammatory cytokines either individually 
or in mixture, can modulate cholestatic and/or cytotoxic responses to antibiotics and 
that the extent of these effects is dependent on the cytokine and the cholestatic 
antibiotic. 
 
Keywords: Drug-induced liver injury, cholestasis; HepaRG cells; inflammatory 
stress, canalicular efflux, bile canaliculi 
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Abbreviations 
AMP ampicillin 
ATB antibiotic 
BA bile acid 
BC bile canaliculi 
BSEP bile salt export pump 
CDF 5 (and 6)-carboxy-2′,7′-dichlorofluorescein 
CDFDA 5(6)-carboxy-2, 7-dichlorofluorescein diacetate (CDFDA) 
CLX cloxacillin 
CRP C-reactive protein 
DMSO dimethyl sulfoxide 
ERY erythromycin  
FLX flucloxacilin 
IL interleukin 
LPS lipopolysaccharide 
LVX levofloxacin 
MTT methylthiazol tetrazolium 
MRP2 multi-drug resistance-associated protein 2 
NAF nafcillin 
PRA penicillinase-resistant antibiotic 
NTCP Na+-dependent taurocholic cotransporting polypeptide 
SM streptomycin 
TNF-α tumor necrosis factor-α 
TVX trovafloxacin. 
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Introduction 
Liver lesions are usually categorized into hepatocellular, cholestatic, or mixed 
(cholestatic and hepatocellular) injury based on the pattern of liver enzyme 
abnormalities. Cholestasis is characterized by accumulation of bile acids (BAs) or 
their conjugated bile salts in the liver and systemic circulation. Both intrahepatic and 
extrahepatic cholestasis has been described in humans and may be due to impaired 
secretion of BAs by hepatocytes or obstruction of either intrahepatic or extrahepatic 
bile ducts. 
Cholestasis is an early and frequent complication in patients with sepsis that is 
characterized by a systemic inappropriate inflammatory response to bacterial 
infection resulting in the release of lipopolysaccharide (LPS) and production of pro-
inflammatory cytokines and other mediators (Chand and Sanyal, 2007) . LPS and 
pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β 
(IL-1β) and interleukin-6 (IL-6), are potent inhibitors of hepatobiliary transport. 
Expression and activities of key sinusoidal and canalicular transporters of 
hepatocytes are reduced and both bile acid-dependent and bile acid-independent 
fractions of bile flow are affected (Elferink et al., 2004; Fardel and Le Vee, 2009). 
Increased levels of intrahepatic BAs have been shown to promote inflammation in 
cholestasis associated with LPS-induced sepsis in mice (Hao et al., 2017). 
Idiosyncratic bland and mixed cholestasis has been observed in clinic following 
treatment with many drugs, including various antibiotics (ATBs). The mechanisms 
underlying idiosyncratic drug-induced liver injury remain poorly understood (Shaw et 
al., 2010). One hypothesis is that an inflammatory stress alters the toxicity threshold 
of an individual, rendering toxic a therapeutic dose of a drug (Ganey et al., 2004). 
The most prescribed antibiotic flucloxacilin (FLX) is thought to cause liver damage, 
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mostly cholestasis, in approximately 8.5 in 100000 patients (Russmann et al., 2005). 
Recently, we reported that FLX and two other penicillinase-resistant antibiotics 
(PRAs), namely cloxacillin (CLX) and nafcillin (NAF), induced cholestatic features at 
much lower concentrations than cytotoxicity in human HepaRG cells while other 
hepatotoxic ATBs such as trovafloxacin (TVX), levofloxacin (LVX) and erythromycin 
(ERY), induced cytotoxicity and cholestasis features at comparable concentrations 
(Burban et al., 2017). All these compounds caused dilatation of BC. However, 
whether these drug-induced cholestatic features can be aggravated in an 
inflammatory context in absence of BA accumulation, remains unclear. As a first 
approach, the present study aimed to investigate whether an inflammatory stress 
could modulate deformation of BC and related disturbances induced by these 
cholestatic drugs using differentiated HepaRG cells. The major pro-inflammatory 
cytokines TNF-α, IL-6 and IL-1β, either individually or combined, were selected to 
create an inflammatory situation before simultaneous treatment with the tested ATBs. 
Our data demonstrate that pro-inflammatory cytokines can aggravate ATB-induced 
cholestatic and cytotoxic effects. 
 
Materials and Methods  
Reagents 
Flucloxacillin (FLX), cloxacillin (CLX), nafcillin (NAF), trovafloxacin (TVX), 
levofloxacin (LVX), erythromycin (ERY), streptomycin (SM), ampicillin (AMP), 
methylthiazol tetrazolium (MTT), N-acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcoumarin (Ac-DEVD-AMC) and 5(6)-carboxy-2, 7-dichlorofluorescein diacetate 
(CDFDA) were purchased from Sigma (St. Quentin Fallavier, France). [3H]-
Taurocholic acid ([3H]-TA) was from Perkin Elmer (Boston, MA). TNF-α, IL-6 and IL-
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
1β were provided by Promocell (Nuremberg, Germany). Other chemicals were of 
reagent grade. 
 
Cell cultures 
All HepaRG cell cultures were prepared from vials of different frozen cell batches and 
incubated with the same HyClone fetal calf serum. Before starting the treatments 
HepaRG cells were differentiated as previously described (Cerec et al., 2007). Cells 
were seeded at a density of 2.6 × 104 cells/cm2 in Williams’ E medium 
supplemented with 2 mM glutamax, 100 U/mL penicillin, 100 µg/mL streptomycin, 
10% HyClone fetal calf serum, 5 µg/mL insulin, and 50 µM hydrocortisone 
hemisuccinate. After 2 weeks, they were shifted to the same medium 
supplemented with 1.7% dimethyl sulfoxide (DMSO) for 2 additional weeks to 
obtain differentiated cultures containing around equal proportions of hepatocyte-
like and progenitor/primitive biliary-like cells. 
 
Cell treatments 
Differentiated HepaRG cells were first incubated in absence or presence of IL-6, IL-
1β and TNF-α, either individually or combined, in a medium containing 2% HyClone 
fetal calf serum and 1% DMSO (final concentration) for 24 h before 
simultaneous incubation with ATBs for 2 or 24 h in the same medium. 
 
C-reactive protein ELISA assay 
C-reactive protein (CRP) was measured in culture media using the CRP DuoSet kit 
(Catalog Number: DY1707, R&D, Abingdon, United Kingdom), according to 
manufacturer’s instructions. Briefly, media were collected after 24 h treatment and 
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stored at −80 °C until analysis; 96-well microplates were coated with mouse anti-
human CRP capture antibody and incubated overnight. A standard curve was 
obtained by using recombinant human CRP at 2-fold serial dilutions from 1000 
pg/mL to 15.6 pg/mL, as recommended by the manufacturer. Samples were diluted 
appropriately and added for 2 h after a saturation step. Biotinylated mouse anti-
human CRP antibody was added for 2 h after washing. Streptavidin-horseradish 
peroxidase and its substrate were used for the revelation step. Optical density was 
read at 450 nm with wavelength correction.  
Caspase-3 activity determination 
After treatment, cells were scrapped in their culture medium to also collect any 
detached cells, centrifuged, washed with phosphate buffered saline and stored as 
pellets at −80 °C. After cell lysis, the Bradford protein assay was used to measure 
the concentration of total protein in each sample and 40 μg proteins were 
incubated with 50 μM Ac-DEVD-AMC in caspase 3 activity buffer (20 mM PIPES 
pH 7.2, 100 mM NaCl, 10 mM dithiotreitol, 1 mM EDTA, 0.1% CHAPS and 10% 
sucrose) at 37 °C for 1 h. Caspase-3-mediated cleavage of the Ac-DEVD-AMC 
peptide was continuously measured by spectrofluorimetry using 
excitation/emission wavelengths of 380/440 nm (Burban et al., 2017). 
 
Cell viability assay 
Cytotoxicity was evaluated by the MTT colorimetric assay. Briefly, the cells were 
seeded in 96-well plates and treated with various concentrations of ATBs in triplicate 
for 24 h. After medium removal, 100 μl serum-free medium containing MTT (0.5 
mg/mL) was added to each well and incubated for 2 h at 37 °C. The water-insoluble 
formazan was dissolved in 100 μl DMSO, and absorbance was measured at 550 nm. 
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Time-lapse cell imaging 
Phase-contrast images of HepaRG cells were captured by time-lapse phase-
contrast videomicroscopy equipped with an AxioCam MRm camera. An inverted 
microscope (Zeiss Axiovert 200 M), equipped with a thermostatic chamber (37 °C 
and 5% CO2), was used to maintain the cells under normal culture conditions 
(Sharanek et al., 2016).  
 
Bile canaliculi area quantification 
Bile canaliculi (BC) area quantification was based on phase-contrast images. After 
capturing of images, BC areas were determined from 9 zones per condition 
counting around 2500 objects in 3 independent experiments using ImageJ 1.48 
software after different times of exposure. Bright objects corresponding to BC were 
segmented by adjusting the shape and area parameters to exclude non-
corresponding objects (Sharanek et al., 2016).  
 
Taurocholic acid uptake  
HepaRG cells were treated with cytokines or ATBs separately or simultaneously for 
24 h and then washed with a standard buffer and incubated with [3H]-TCA for 30 min 
in presence and absence of Na+, to evaluate Na+-dependent taurocholic 
cotransporting polypeptide (NTCP) activity. After 30 min incubation, cells were 
washed twice with phosphate buffered saline and lysed with 0.1N NaOH. 
Accumulation of radiolabeled substrate was determined through scintillation counting. 
Taurocholate accumulation values in presence of sodium minus accumulation values 
in absence of sodium represented NTCP activity (Antherieu et al., 2013). Data are 
the mean ± SEM of 3 independent experiments. Results are expressed relative to the 
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levels found in untreated (control) cells, arbitrarily set at 100%. *p < 0.05 compared 
with untreated cells.  
 
Taurocholic acid efflux 
TCA is mainly effluxed by the bile salt export pump (BSEP). To investigate the effects 
of ATBs and cytokines on TCA efflux, cell cultures were washed with a standard 
buffer containing Ca2+ and Mg2+, exposed to 43.3 nM [3H]-TCA for 30 min to induce 
its intracellular accumulation, washed and then incubated with ATBs and/or cytokines 
for 2 h. All these steps were performed using the standard buffer. After incubation, 
cells were washed and scraped in 0.1 N NaOH and the remaining radiolabeled 
substrate was measured through scintillation. [3H]-TCA efflux was determined based 
on its accumulation in cell layers (cells + BC) and calculated relative to the controls 
using the following formula: [3H]-TCA efflux = [3H]-TCA accumulation in cell layers 
Control / [3H]-TCA accumulation in cell layers Tested compound *100 (Sharanek et 
al., 2016). 
 
Carboxy-dichlorofluorescein efflux 
After treatment cells were washed with warm Williams’ E medium without phenol 
red and any supplement, and incubated with the same medium containing 3 μM 
CDFDA for 30 min at 37 °C. CDFDA passively crossed the plasma membrane and 
upon hydrolysis by intracellular esterases, was converted to fluorescent CDF 
(excitation/emission: 488/509 nm) and directed towards the biliary pole by 
membrane transporters, particularly the multi-drug resistance associated protein 2 
(MRP2). After washing, imaging was performed using a Cellomics ArrayScan VTI 
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HCS Reader (Thermo Fisher Scientific). The number of CDF-accumulating BC was 
quantified using ImageJ 1.48 software (Burban et al., 2017). 
 
Statistical analysis 
A one-way ANOVA with a multiple comparison test (GraphPad Prism 5.00) was 
performed to compare the data. Each value corresponded to the mean ± SEM of 
three independent experiments. Data were considered significantly different at 
p < 0.05. 
 
Results 
Effects of pro-inflammatory cytokines on antibiotic-induced cytotoxicity in 
HepaRG cells 
First, we investigated cytotoxic effects of the three tested pro-inflammatory cytokines, 
TNF-α, IL-6, and IL-1β, either individually or combined, in HepaRG cells. At 
concentrations that have been widely used in in vitro studies, i.e. TNF-α (10 ng/ml), 
IL-6 (5 ng/ml) and IL-1β (0.5 ng/ml) (Al-Attrache et al., 2016; Bachour-El Azzi et al., 
2014; Rubin et al., 2015), none of these cytokines caused any cytotoxicity, as 
evaluated by caspase-3 activity and MTT assays after 2 daily repeated additions. 
Similarly, when added as a mixture the 3 pro-inflammatory cytokines did not exert 
any significant effect (Figure 1A). Generation of an in vitro inflammatory response to 
these cytokines at the tested concentrations was validated by determination of 
secreted CRP levels after 24 h incubation. All cytokines caused statistically 
significant increase in secreted CRP amounts, reaching 3-, 14- and 17-fold with TNF-
α, IL-6 and IL-1β respectively, compared with unexposed cell cultures; treatment with 
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the cytokine mixture further enhanced CRP secretion levels reaching 37-fold (Figure 
1B). 
Cytotoxicity of six cholestatic (FLX, CLX, NAF, TVX, LVX and ERY) and two non 
cholestatic (AMP and SM) antibiotics was also estimated in HepaRG cells using 
caspase-3 activity assay after 24 h treatment. To verify whether ATB-induced 
apoptotic effects were affected by co-treatment with cytokines, HepaRG cells were 
first incubated with TNF-α, IL-6 and IL-1β either individually or combined before 
simultaneous co-treatment with the tested ATBs for additional 24 h. As previously 
reported (Burban et al., 2018), the tested hepatotoxic ATBs induced dose-dependent 
enhancement of caspase-3 activity. NAF was slightly more cytotoxic than the two 
other PRAs. When co-added with PRAs, individual cytokines were ineffective while 
their mixture enhanced around 2-fold caspase-3 activity levels compared to the 
values measured with PRAs alone (Figure 2 A-C). 
At 5 µM TVX did not augment caspase-3 activity whereas its co-addition with either 
of the three cytokines caused around 3-fold increase. At 20 and 100 µM TVX co-
added with TNF-α, IL-6 and IL-1β , further enhanced caspase-3 activity, reaching 23-, 
14.6- and 26-fold respectively with the highest concentration compared to 8.6-fold 
when added alone. Notably, caspase-3 activity elevation reached 36-fold when 100 
µM TVX was co-added with the cytokine mixture (Figure 2D). LVX alone had no 
significant effects at concentrations up to 2.5 mM, in the presence of individual 
cytokines; by contrast, at this high concentration caspase-3 activity was enhanced 
5.5-fold in presence of the cytokine mixture (Figure 2E). 
ERY also augmented dose-dependently caspase 3 activity, reaching around 4- and 
12.8-fold at 0.5 and 1 mM respectively after 24 h; while individual cytokines were 
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ineffective their mixture reduced ERY-induced activity to around 2.5- and 5-fold 
respectively (Figure 2F).  
The two non cholestatic non hepatotoxic ATBs SM and AMP were used as controls: 
SM was slightly cytotoxic, causing 2.2-fold induction of caspase-3 activity only at 12 
mM while AMP had no effect at concentrations up to 24 mM. Co-treatment with the 
cytokines, either individually or in mixture, was ineffective regardless of the 
concentration of these two ATBs (Figure 2G and H).  
Cytotoxicity of 5 ATBs in presence or absence of the 3 cytokines was also estimated 
using the MTT assay; only aggravation of TVX toxicity by TNF-α was observed 
(Supplemental Figure 1).  
 
Effects of inflammatory stress on ATB-induced cholestatic features 
Based on a previous study (Burban et al., 2018), ATBs were used at the following 
concentrations: 2 mM FLX, 2 mM CLX, 2 mM NAF, 20 µM TVX, 0.5 mM LVX, 0.1 
mM ERY, 12 mM SM and 24 mM AMP. At these concentrations none of the tested 
ATBs was significantly cytotoxic even when co-incubated with cytokines (Figure 2). 
No increase in caspase 3 activity and no morphological changes, except BC 
dilatation with cholestatic ATBs, were evidenced. BC deformation, an important 
feature of drug-induced cholestasis (Sharanek et al., 2016), was analyzed during 24 
h following addition of ATBs, either alone or in presence of individual or combined 
cytokines, using time-lapse microscopy. All tested cholestatic ATBs caused BC 
dilatation as early as 2 h treatment. PRAs induced higher dilatation of BC than TVX, 
LVX and ERY (Figure 3A and B). The negative controls SM and AMP were 
ineffective (Figure 3A and C). The three cytokines, either individually or in mixture, 
did not alter BC morphology (Figure 3A and D). However, co-treatment with IL-6 and 
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IL-1β but not with TNF-α, significantly aggravated BC dilatation induced by all tested 
cholestatic ATBs. No further aggravation was observed with the cytokine mixture 
(Figure 3A and B). 
As BC deformations could be associated with bile flow failure, we analyzed whether 
cholestatic ATBs impaired efflux activity by measuring TCA accumulation in cell 
layers (intracelllular + canalicular accumulation) and canalicular accumulation of the 
fluorescent probe CDF. As previously reported cytokines inhibited BA uptake via 
inhibition of the NTCP transporter (Bachour-El Azzi et al., 2014; Le Vee et al., 2009). 
In our experimental conditions TNF-α, IL-6 and IL-1β repressed NTCP activity by 40 
to 75% after 24h exposure (Figure 4A), indicating that TCA accumulation in cell 
layers could not be correctly analyzed after 24 h pre-incubation with pro-inflammatory 
cytokines. Consequently, HepaRG cells were directly treated with cytokines and 
ATBs either separately or combined. Inhibition of [3H]-TCA efflux was observed with 
the 6 cholestatic drugs, especially FLX (80%) and NAF (65%). At the tested 
concentrations the 3 cytokines showed only a trend to accumulation of TCA in cell 
layers and did not enhance TCA accumulation induced by the cholestatic drugs 
(Figure 4B and C). 
After 2 h CDFDA addition, fluorescent CDF was well visualized in BC lumen of 
untreated and ATB-treated HepaRG cells (Figure 5A). Even though either individually 
or combined cytokines did not modulate CDF canalicular efflux (Figure 5D), their co-
treatment with cholestatic ATBs resulted in significant reduction of CDF canalicular 
accumulation reaching between 40% and 80% (Figure 5A and B). The significant 
inhibition of CDF canalicular efflux by PRAs at 2 mM was aggravated in presence of 
pro-inflammatory cytokines (Supplemental Figure 2). To better demonstrate effects of 
cytokine co-addition, PRAs were used at a lower concentration (0.5 mM) (Figure 5A 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
and B). TNF-α caused the lowest effects. No further reduction of CDF accumulation 
was observed when the cells were co-treated with mixed versus individual cytokines. 
SM and AMP were ineffective, even in presence of individual or combined cytokines 
(Figure 5A and C). 
 
Discussion 
Several reports have shown that modest activation of the innate immune system by 
inflammagens such as LPS, can markedly enhance hepatotoxic response to various 
drugs, such as amiodarone, diclofenac and TVX (Roth et al., 2017). However, 
influence of an inflammatory stress on drug-induced liver injury has mostly been 
focused on cytotoxic damage, cholestatic effects remaining poorly investigated. A 
direct inflammatory response to LPS (Aninat et al., 2008) and pro-inflammatory 
cytokines (Bachour-El Azzi et al., 2014; Klein et al., 2015; Rubin et al., 2015) has 
also been evidenced in HepaRG cells. In the current work using these cells, we 
showed that pro-inflammatory cytokines enhanced cholestatic features and/or 
cytotoxic damage caused by ATBs exhibiting various chemical structures and known 
to induce liver injury in some patients.  
 
TVX was the most potent cytotoxic drug among the tested ATBs and its cytotoxicity 
was potentiated by TNF-α and IL-1β. In agreement, these two cytokines have been 
reported to be predominantly involved in drug-cytokines synergies (Cosgrove et al., 
2009; Fredriksson et al., 2014). High sensitivity to TVX in an inflammatory context is 
supported by several previous works using in vitro and in vivo models and has been 
related to C-Jun N-terminal kinase activation (Beggs et al., 2014; Maiuri et al., 2015). 
Contrary to TVX, the other fluoroquinolone LVX is generally considered a safe 
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antibiotic although rare cases of hepatotoxicity have been reported in clinic (Levine et 
al., 2014). Accordingly, this drug has to be used at high concentrations to cause 
cytotoxic damage in HepaRG cells (Burban et al., 2018) and contrary to TVX, it was 
not more cytotoxic with TNF-α than with other cytokines, supporting previous 
observations (Cosgrove et al., 2009). 
As other macrolide ATBs, ERY has been shown to form P450-Fe2+-metabolite 
complexes after CYP3A4-mediated activation (Larrey et al., 1983; Yamazaki et al., 
1996). In the present study, ERY was found to be less cytotoxic when co-added with 
the cytokine mixture while individual cytokines were ineffective. The effect of the 
mixture could result from a faster decrease in the formation of reactive metabolites, 
related to early higher inhibition of CYP3A4 activity and/or to a stronger activation of 
defense mechanisms. Further work is required to clarify this point.  
LPS and pro-inflammatory cytokines TNF-α, IL-1β and IL-6 can stimulate hepatocyte 
signaling responses through activation of a diversity of intracellular signal 
transduction pathways, such as MAPKs and JNK (Fardel and Le Vee, 2009). As 
previously reported (Burban et al., 2017), all presently tested hepatotoxic ATBs 
induced ER stress followed by oxidative stress. Whether the cytokines aggravated 
cytotoxic and cholestatic effects through these stress pathways required further 
investigation.  
As recently observed (Burban et al., 2018), all tested cholestatic ATBs caused early 
BC dilatation and other associated cholestatic features in absence of cytotoxicity. 
Since cholestasis is an early and common event associated with sepsis, it was 
tempting to postulate that cholestatic features induced by cholestatic drugs could be 
aggravated in human hepatocytes cultured in an inflammatory context. Our data 
demonstrate that, although they had no effect on BC morphology when added alone, 
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IL-6 and IL-1β but not TNF-α aggravated BC dilatation caused by all cholestatic ATBs 
in HepaRG hepatocytes. Noticeably, TNF-α was also found to be ineffective on 
diclofenac-induced BC deformation (Al-Attrache et al., 2016). Importantly, cytokine 
effects were evaluated in a medium containing 2% bovine serum (i.e. containing only 
around 365 nM BAs) (Sharanek et al., 2015). Consequently, whatever the 
experimental condition no BA intracellular accumulation could occur.  
Cholestasis is associated with impaired bile flow and several studies have shown that 
pro-inflammatory cytokines can alter expression and/or activity of various sinusoidal 
and canalicular transporters (Diao et al., 2010; Elferink et al., 2004). In the present 
study, none of the tested cytokines was found to markedly alter efflux of TCA, a 
BSEP substrate, and efflux of CDF, a MRP2 substrate. Moreover, they did not 
enhance TCA accumulation in cell layers induced by ATBs, likely resulting from 
BSEP inhibition. However they further reduced CDF canalicular accumulation 
observed with ATBs. Noticeably, discrepant data have been reported on the effects 
of pro-inflammatory cytokines on these two main canalicular transporters as well as 
other transporters (Bachour-El Azzi et al., 2014; Diao et al., 2010; Le Vee et al., 
2009). They could be explained by the use of different experimental culture 
conditions as well as the choice of the parameter tested, e.g. expression or activity of 
the tested transporters, concentrations of cytokines and drugs and duration of 
treatment. However, the 3 cytokines were found to repress NTCP in agreement with 
other studies (Fardel and Le Vee, 2009), and to cause significant inhibition of CDF 
canalicular accumulation even in the presence of ATB concentrations that did not 
modulate CDF efflux activity. Whether this could be explained by further inhibition of 
transporters, some diffusion through disrupted tight-junctions or another mechanism, 
warrants further investigation.  
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
Importantly, culture conditions could also influence the response of HepaRG cells to 
pro-inflammatory cytokines. Indeed, these cells were incubated in a medium 
containing 2% serum and 1% DMSO that certainly had some protective effects. 
Moreover, HepaRG cells have a high detoxifying capacity (Guillouzo and Guguen-
Guillouzo, 2018). Therefore, it might be postulated that cytokine effects could be 
amplified by incubating the cells in serum- and DMSO-free medium. However, 
previous studies have shown that in presence of 2% serum limited changes if any 
were observed in drug biokinetics in HepaRG cells (Broeders et al., 2015; Pomponio 
et al., 2015). 
Molecular mechanisms as to how BAs initiate liver injury are not completely 
elucidated. Cholestatic liver injury has been first associated with accumulation of 
toxic BAs resulting in mitochondrial dysfunction and cell death (Galle et al., 1990). 
However, much lower BA concentrations were found to induce toxic damage in vivo 
compared to in vitro, suggesting the involvement of sterile inflammation and innate 
immunity in the initial injury (Woolbright and Jaeschke, 2012). Recent studies have 
shown that at high concentrations BAs triggered early hepatocyte production of 
cytokines of which release enhanced neutrophil chemotaxis and liver infiltration in 
mice (Cai et al., 2017; Woolbright and Jaeschke, 2016). These findings were 
supported by the observation that periportal neutrophil infiltration correlated with 
serum alanine aminotransferase levels in cholestatic patients (Cai et al., 2017). 
Cholestatic drugs can cause rapid cellular accumulation of toxic hydrophobic BAs in 
HepaRG cells in absence of major cellular injury when exogenous BAs are added to 
the culture medium (Burban et al., 2019; Sharanek et al., 2017). In the current study 
we show that at the tested concentrations the two pro-inflammatory cytokines IL6 and 
IL-1β enhanced BC dilatation induced by cholestatic ATBs in absence of obvious cell 
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injury. In vivo, cholestatic ATBs and other drugs can cause bland (e.g. FLX) or mixed 
(e.g. TVX) cholestasis, suggesting that in addition to environmental factors drug 
related factors are important in the occurrence of cholestasis implicating different 
mechanisms and activation of diverse signaling pathways. Further investigations on 
interactions between BAs, pro-inflammatory cytokines and/or immune cells and 
cholestatic drugs using different experimental conditions should permit to better 
understand the role of an inflammatory context in the potential of certain drugs to 
induce cholestasis.  
In conclusion, our results demonstrate that certain pro-inflammatory cytokines can 
aggravate BC dilatation and CDF efflux inhibition induced by cholestatic antibiotics in 
HepaRG hepatocytes and that these effects can be observed in absence of cellular 
damage, suggesting that cholestatic features can be more sensitive than cellular 
injury to an inflammatory stress. 
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Legends to figures 
Figure 1. Effects of cytokines on caspase-3 activity and C-reactive protein 
release in HepaRG cell cultures exposed to individual or mixed pro-
inflammatory cytokines.  
HepaRG cell cultures were incubated with TNF-α (10 ng/ml), IL-6 (5 ng/ml) and IL-1β 
(0.5 ng/ml) individually or in mixture for 24 h. (A) Cytotoxicity was estimated using the 
caspase-3 activity assay. (B) CRP secretion levels were measured in the medium 
using ELISA assay. Caspase-3 activity is expressed as fold change compared to 
unexposed cultures arbitrarily set at a value of 1 and CRP as ng/ml. Data represent 
the means ± SEM of 3 independent experiments. *p < 0.05 compared to unexposed 
cells; $p < 0.5 cytokine mixture compared to individual cytokines. 
 
Figure 2. Cytotoxic effects of antibiotics and pro-inflammatory cytokines in 
HepaRG cells.  
(A-H) HepaRG cell cultures were incubated with different concentrations of FLX (A), 
CLX (B), NAF (C) TVX (D), LVX (E), ERY (F), SM (G) and AMP (H) in the absence or 
presence of cytokines. Cells were first incubated with cytokines for 24 h before 
simultaneous incubation with ATBs for another 24 h. Cytokines were used either 
individually or in mixture at the following concentrations: TNF-α (10 ng/ml), IL-6 (5 
ng/ml) and IL-1β (0.5 ng/ml). Cytotoxicity was measured using the caspase-3 activity 
assay. Data were expressed relative to those obtained with untreated cells arbitrarily 
set at 1. They represent the means ± SEM of 3 independent experiments. *p < 0.05 
compared to untreated cells; #p < 0.05 ATB + cytokines individually compared to ATB 
alone; $p < 0.05 ATB + cytokine mixture compared to ATB alone and ATB + individual 
cytokine. 
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Figure 3. Influence of antibiotics and pro-inflammatory cytokines on bile 
canaliculi structures of HepaRG cells. 
(A) Representative phase-contrast images showing BC dilatation (arrows) in 
HepaRG cells treated for 2 h with non-cytotoxic ATB concentrations in absence or 
presence of individual and combined pro-inflammatory cytokines. Cells were first 
incubated with cytokines for 24 h before simultaneous incubation with ATBs. Phase-
contrast images were captured using time-lapse microscopy (bar = 50 µm).  
 (B-D) Mean bile canaliculi (BC) areas of HepaRG hepatocytes treated with ATBs for 
2 h in absence or presence of individual or combined cytokines or exposed to 
cytokines alone, using ImageJ 1.48 software as described in the Materials and 
Methods section. Data were expressed as the fold change in the BC mean area 
relative to the mean area of untreated cells arbitrarily set at a value of 1. They 
represent the means ± SEM of 3 independent experiments. *p < 0.05 compared to 
untreated cells; #p < 0.05 ATB + individual cytokines compared to ATB alone. (A-D): 
ATBs were used at the following concentrations: FLX, CLX and NAF: 2 mM; TVX: 20 
µM; LVX: 2 mM; ERY: 100 µM AMP: 24 mM and SM: 15mM. 
 
Figure 4. [3H]-TCA uptake and efflux in HepaRG cells treated with antibiotics 
and pro-inflammatory cytokines separately or in combination 
(A) [3H]-TCA uptake in HepaRG cells after 24 h treatment with pro-inflammatory 
cytokines separately or in combination. (B,C) [3H]- efflux in HepaRG cells treated with 
pro-inflammatory cytokines alone (B) or co-treated with pro-inflammatory cytokines 
and the different ATBs (C) for 2 h. Cytokine concentrations were the following: TNF-α 
(10 ng/ml), IL-6 (5 ng/ml) and IL-1β (0.5 ng/ml). The data were expressed relative to 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
that of untreated cells arbitrarily set at 100% and are presented as the means +/- 
SEM of 3 independent experiments. *p < 0.05 compared with that of the untreated 
cells.  
Figure 5. Effects of antibiotics and pro-inflammatory cytokines on CDF efflux in 
HepaRG cells.  
(A) Representative fluorescent images showing CDF canalicular efflux in HepaRG 
hepatocytes treated for 2 h with the different ATBs in absence or presence of the 
cytokine mixture. Cells were first incubated with cytokines for 24 h before 
simultaneous incubation with ATBs for 2 h. (B-D) Quantification of CDF accumulation 
in BC of HepaRG cells after 2 h treatment with ATBs in absence or presence of 
individual or combined cytokines or exposed to cytokines alone (D), using imageJ 
1.48 software as described in the Materials and Methods section. Fluorescent images 
were obtained with a Cellomics ArrayScan VTI HCS Reader (bar = 50 µm). Hoechst-
labelled nuclei in blue. Data were expressed relative to those of untreated cells 
arbitrarily set at 100%. They represent the means ± SEM of 3 independent 
experiments. *p < 0.05 compared to untreated cells; #p < 0.05 ATB + individual 
cytokines compared to ATB alone. 
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Highlights  
 HepaRG cells were co-exposed to cholestatic antibiotics and pro-inflammatory cytokines. 
 Bile canaliculi dilatation induced by cholestatic antibiotics was enhanced by IL-6 and IL-1β.  
 Efflux inhibition of CDF, a MRP2 substrate, was aggravated in response to pro-inflammatory cytokines. 
 Antibiotic-induced cholestatic changes were more sensitive than cytotoxicity to inflammatory stress . 
 The extent of effects were dependent on the cytokine and the cholestatic drug. 
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